News & Updates

COVID-19 vaccines promising in multiple myeloma patients
COVID-19 vaccines promising in multiple myeloma patients
05 Jan 2022
Abdominal adipose tissue radiodensity predicts survival after colorectal cancer
Abdominal adipose tissue radiodensity predicts survival after colorectal cancer
04 Jan 2022
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022 byAudrey Abella

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022
Breast cancer survivors at greater risk of non-Hodgkin lymphoma
Breast cancer survivors at greater risk of non-Hodgkin lymphoma
03 Jan 2022
Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
30 Dec 2021
Early mortality high among multiple myeloma patients
Early mortality high among multiple myeloma patients
30 Dec 2021

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.

Early mortality high among multiple myeloma patients
30 Dec 2021